Status:

UNKNOWN

Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With Rituximab

Lead Sponsor:

Rambam Health Care Campus

Collaborating Sponsors:

Technion, Israel Institute of Technology

Conditions:

Lymphoma

Eligibility:

All Genders

55+ years

Phase:

NA

Brief Summary

Background: The ability of the immune system to function declines with aging. This is reflected by a marked decrease in the responsiveness to vaccinations and to infectious agents. Consequentially, t...

Eligibility Criteria

Inclusion

  • 55 years and older
  • lymphoma
  • rituximab

Exclusion

  • disease remission

Key Trial Info

Start Date :

February 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00863187

Start Date

February 1 2009

Last Update

March 17 2009

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Assessing Antibody Responsiveness to Hepatitis B Vaccine in Aged Lymphoma Patients Undergoing Treatment With Rituximab | DecenTrialz